Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
İlgili Semboller 1
XENE XENE
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.